ArticlePsychopharmacology2011

AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.

Mark D Black et al.PubMed ↗Publisher ↗

No numbers read from the abstract.